Literature DB >> 27450937

An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.

E David Crawford1, Matt T Rosenberg2, Alan W Partin3, Matthew R Cooperberg4, Michael Maccini5, Stacy Loeb6, Curtis A Pettaway7, Neal D Shore8, Paul Arangua5, John Hoenemeyer5, Mike Leveridge9, Michael Leapman10, Peter Pinto11, Ian M Thompson12, Peter Carroll10, James Eastham13, Leonard Gomella14, Eric A Klein15.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27450937      PMCID： PMC5568096          DOI： 10.1016/j.urology.2016.07.001

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  23 in total

1.  Prostate Cancer Screening.

Authors:  Scott E Eggener; Adam S Cifu; Chadi Nabhan
Journal:  JAMA       Date:  2015-08-25       Impact factor: 56.272

2.  Expected population impacts of discontinued prostate-specific antigen screening.

Authors:  Roman Gulati; Alex Tsodikov; Ruth Etzioni; Rachel A Hunter-Merrill; John L Gore; Angela B Mariotto; Matthew R Cooperberg
Journal:  Cancer       Date:  2014-07-25       Impact factor: 6.860

3.  Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA).

Authors: 
Journal:  Oncology (Williston Park)       Date:  2000-02       Impact factor: 2.990

4.  PSA screening: determinants of primary-care physician practice patterns.

Authors:  G E Tasian; M R Cooperberg; M B Potter; J E Cowan; K L Greene; P R Carroll; J M Chan
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-11-29       Impact factor: 5.554

5.  Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone.

Authors:  E David Crawford; Judd W Moul; Kyle O Rove; Curtis A Pettaway; Lois E Lamerato; Alexa Hughes
Journal:  BJU Int       Date:  2011-06-28       Impact factor: 5.588

6.  The impact of PLCO control arm contamination on perceived PSA screening efficacy.

Authors:  Roman Gulati; Alex Tsodikov; Elisabeth M Wever; Angela B Mariotto; Eveline A M Heijnsdijk; Jeffrey Katcher; Harry J de Koning; Ruth Etzioni
Journal:  Cancer Causes Control       Date:  2012-04-10       Impact factor: 2.506

7.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

8.  Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.

Authors:  E David Crawford; Paul F Pinsky; David Chia; Barnett S Kramer; Richard M Fagerstrom; Gerald Andriole; Douglas Reding; Edward P Gelmann; David L Levin; John K Gohagan
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

9.  Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

Authors:  Claire de la Calle; Dattatraya Patil; John T Wei; Douglas S Scherr; Lori Sokoll; Daniel W Chan; Javed Siddiqui; Juan Miguel Mosquera; Mark A Rubin; Martin G Sanda
Journal:  J Urol       Date:  2015-01-28       Impact factor: 7.450

10.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Authors:  Andrew J Vickers; David Ulmert; Daniel D Sjoberg; Caroline J Bennette; Thomas Björk; Axel Gerdtsson; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; Hans Lilja
Journal:  BMJ       Date:  2013-04-15
View more
  4 in total

Review 1.  Is a Positive Developmental-Behavioral Screening Score Sufficient to Justify Referral? A Review of Evidence and Theory.

Authors:  R Christopher Sheldrick; Daryl Garfinkel
Journal:  Acad Pediatr       Date:  2017-03-07       Impact factor: 3.107

2.  Engaging the primary care community to encourage appropriate prostate cancer screening.

Authors:  Malhar P Patel; Ariel Schulman; Kevin P Shah; John B Anderson; Thomas J Polascik
Journal:  Ther Adv Urol       Date:  2017-10-16

Review 3.  Prostate cancer screening-when to start and how to screen?

Authors:  Kimia Kohestani; Marina Chilov; Sigrid V Carlsson
Journal:  Transl Androl Urol       Date:  2018-02

4.  Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.

Authors:  Tobias Nordström; Jan Adolfsson; Henrik Grönberg; Martin Eklund
Journal:  BMC Urol       Date:  2017-10-03       Impact factor: 2.264
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.